

# Vincenzo Di Nunno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9308341/publications.pdf>

Version: 2024-02-01

106  
papers

1,428  
citations

361296

20  
h-index

434063

31  
g-index

109  
all docs

109  
docs citations

109  
times ranked

1980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018, 64, 11-20.	3.4	76
2	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 68-73.	3.4	64
3	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-8.	1.0	63
4	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , 2021, 10, CNS72.	1.2	54
5	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	0.6	52
6	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , 2020, 77, 761-763.	0.9	51
7	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021, 26, 865-878.	1.9	39
8	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 631-643.	1.0	38
9	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	1.7	38
10	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
11	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017, 60, 152-157.	3.4	35
12	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2018, 13, 705-714.	1.7	35
13	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	1.7	29
14	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e871-e877.	0.9	28
15	Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e339-e344.	0.9	28
16	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 80-85.	3.4	27
17	Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 105-106.	0.8	27
18	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	1.1	23
20	Cabozantinib-related cardiotoxicity: a prospective analysis in a <i>real-world</i> cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1283-1289.	1.1	21
21	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
22	BAP1 in solid tumors. <i>Future Oncology</i> , 2019, 15, 2151-2162.	1.1	20
23	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 457-473.	1.6	19
24	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 124-132.	2.0	18
25	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
26	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019, 11, 1507-1521.	1.0	17
27	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e83-e90.	0.9	17
28	Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. <i>Immunotherapy</i> , 2020, 12, 1111-1114.	1.0	17
29	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 32-40.	0.9	17
30	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1021-1025.	0.9	16
31	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
32	Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward. <i>Immunotherapy</i> , 2021, 13, 879-883.	1.0	16
33	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	2.0	15
34	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019, 11, 1225.	1.7	15
35	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021, 11, 342.	1.3	15
36	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018, 10, 65-77.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	1.5	14
38	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 996.	1.3	14
39	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2020, 11, 4582-4592.	0.8	14
40	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020, 16, 1433-1439.	1.1	14
41	Future perspectives for personalized immunotherapy in renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1049-1052.	1.4	13
42	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , 2020, 16, 1053-1063.	1.1	13
43	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , 2020, 40, 211-226.	1.1	13
44	Atezolizumab for platinum-treated metastatic urothelial carcinoma. <i>Lancet, The</i> , 2018, 391, 716-718.	6.3	11
45	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , 2021, 11, 1852.	1.3	11
46	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2022, 39, 165-177.	1.3	11
47	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020, 21, 1463-1475.	1.0	10
48	Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 710-715.	0.7	9
49	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 569-577.	1.6	9
50	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	0.7	9
51	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
52	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	1.4	9
53	Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma. <i>Chinese Clinical Oncology</i> , 2019, 8, S21-S21.	0.4	9
54	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1333-1353.	1.1	9

#	ARTICLE	IF	CITATIONS
55	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance. <i>Frontiers in Oncology</i> , 2022, 12, 852950.	1.3	9
56	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 169-175.	0.4	8
57	Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. <i>Future Oncology</i> , 2018, 14, 2997-2999.	1.1	7
58	Glioneuronal tumors: clinicopathological findings and treatment options. <i>Future Neurology</i> , 2020, 15, .	0.9	7
59	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021, 145, 171-178.	1.3	7
60	Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 80-87.	0.9	7
61	Tumor-Associated Microenvironment of Adult Gliomas: A Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
62	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564.	1.1	6
63	Re: Arnaud MÃ©jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>N Engl J Med</i> 2018;379:417â€“27. <i>European Urology Oncology</i> , 2019, 2, 340-341.	2.6	6
64	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020, 87, 3-10.	0.3	6
65	IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , 2021, 221, 153445.	1.0	6
66	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , 2016, 27, 353-363.	0.7	5
67	Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. <i>Eur Urol</i> 2018;73:560â€“9. <i>European Urology</i> , 2018, 74, e118-e119.	0.9	5
68	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 207-217.	1.5	5
69	How to face cancer treatment in the COVID-19 era. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 429-432.	1.1	5
70	Cabazitaxel in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1286-1286.	13.9	5
71	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , 2021, 221, 153447.	1.0	5
72	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , 2022, 14, 169-172.	1.0	5

#	ARTICLE	IF	CITATIONS
73	Machine learning in neuro-oncology: toward novel development fields. <i>Journal of Neuro-Oncology</i> , 2022, 159, 333-346.	1.4	5
74	Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. <i>Lancet</i> 2018;392:2353-66. <i>European Urology Oncology</i> , 2020, 3, 390.	2.6	4
75	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04604.	0.2	4
76	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1265-1272.	1.1	4
77	Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. <i>Lancet Oncol</i> 2018;19:405-15. <i>European Urology</i> , 2018, 74, e50.	0.9	3
78	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
79	CheckMate 214 patient-reported outcomes: listening to our patients. <i>Lancet Oncology</i> , The, 2019, 20, 179-180.	5.1	3
80	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021, 10, 1581-1587.	0.6	3
81	Immunotherapy in elderly patients: should we stay or should we go?. <i>Future Oncology</i> , 2020, 16, 973-974.	1.1	3
82	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. <i>Immunotherapy</i> , 0, , .	1.0	3
83	The role of precision medicine for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 369-377.	0.4	2
84	Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> 2018;73:62-8. <i>European Urology</i> , 2018, 73, e72.	0.9	2
85	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , 2018, 29, 911-913.	0.7	2
86	New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?. <i>European Urology Oncology</i> , 2019, 2, 471.	2.6	2
87	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019, 15, 563-565.	1.1	2
88	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	2
89	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28. <i>European Urology Oncology</i> , 2019, 2, 603-604.	2.6	1
90	743P Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC). <i>Annals of Oncology</i> , 2020, 31, S577.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. Tumori, 2021, , 030089162110172.	0.6	1
92	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. Clinical Drug Investigation, 2021, 41, 757-773.	1.1	1
93	Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?. Journal of Clinical Oncology, 2020, 38, 707-707.	0.8	1
94	Immune checkpoint inhibitors for metastatic bladder cancer. Translational Cancer Research, 2017, 6, S720-S732.	0.4	1
95	Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.. Journal of Clinical Oncology, 2020, 38, 754-754.	0.8	1
96	Quick steps toward precision medicine in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 283-285.	0.4	0
97	Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?. Lancet Oncology, The, 2018, 19, e437.	5.1	0
98	Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462â€“48. European Urology, 2018, 74, e12-e13.	0.9	0
99	367MO Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective, observational study. Annals of Oncology, 2020, 31, S399.	0.6	0
100	378P MGMT status influences prognosis of patients with IDH wild type grade III gliomas. Annals of Oncology, 2020, 31, S402-S403.	0.6	0
101	Adjuvant therapy in renal cell carcinomaâ€”is pharmacogenomics assessment another element to select our patients?. Annals of Translational Medicine, 2019, 7, S38-S38.	0.7	0
102	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 572-572.	0.8	0
103	Optimizing renal function and outcome of patients with cT2 renal cell carcinoma. Annals of Translational Medicine, 2019, 7, S39-S39.	0.7	0
104	N-Myc a key gene promoting a worst prostate cancer progression. Translational Cancer Research, 2019, 8, E15-E17.	0.4	0
105	MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas.. Journal of Clinical Oncology, 2020, 38, 2523-2523.	0.8	0
106	PATH-15. NON-CANONICAL IDH 1 AND IDH 2 MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH GLIOMAS: RESULTS OF A META-ANALYSIS. Neuro-Oncology, 2021, 23, vi117-vi118.	0.6	0